BIOMARIN PHARMACEUTICAL INC — Form 8-K

BioMarin reported Q3 2026 total revenues of $1,025 million, up 32% year-over-year, driven by the April 27, 2026 acquisition of Amicus Therapeutics (GALAFOLD $152M, POMBILITI+OPFOLDA $49M quarterly revenue). However, the company lowered full-year 2026 Non-GAAP Diluted EPS guidance to $2.80–$3.10 (from $4.90–$5.10) due to $320 million in pre-tax acquired IPR&D charges from the Alesta Therapeutics acquisition and $83 million from the BMN 450 license agreement, representing $1.55 and $0.32 per-share headwinds respectively. GAAP net loss widened to $(123)M from $(31)M YoY due to intangible amortization, debt interest, and restructuring costs; Non-GAAP income grew to $45M from $22M.